This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI. Their new platform, built by a team of biologists and computer scientists, is part of a global movement to democratize and accelerate protein design for medical breakthroughs.
The next-generation sequencing (NGS) market is experiencing rapid growth, which is expected to continue for the foreseeable future. Research by Markets and Markets projects the market to grow from $12.13 billion in 2023 to about $23.55 billion by 2029, a compound annual growth rate (CAGR) of approximately 13.2 percent. 1 Emergen Research attributes this to the advantages of high-throughput sequencing technologies and declining sequencing costs. 2 This trend reflects the increasing demand for g
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.
Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.
Key projects By Maria Nemchuk July 8, 2025 Breadcrumb Home Machine Learning for Health (ML4H) Key projects Our key projects span a diverse set of machine learning applications designed to accelerate discovery and improve clinical care. From foundational multimodal models to targeted disease prediction, phenotyping, and drug repurposing, ML4H combines large-scale data, deep clinical insight, and cutting-edge AI methods to drive innovation across cardiology, neurology, and beyond.
Dr Eleni Lagkadinou is on a mission to fast-track the future of cancer care. As Vice President of Oncology Early Development (OED) at AbbVie , she leads the charge on translating bold scientific ideas into real-world impact – and she’s doing it with a focus on some of the most tenacious cancers out there. With a background spanning drug development, clinical strategy and translational research, Eleni brings more than two decades of experience to the role.
TUESDAY, July 8, 2025 — More Florida teens are roaming the streets packing heat, a new study says.Handgun carrying among Florida middle and high school students increased by 65% between 2002 and 2022, researchers reported July 7 in the journal P.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A new leap in lab automation is shaking up how scientists discover materials. By switching from slow, traditional methods to real-time, dynamic chemical experiments, researchers have created a self-driving lab that collects 10 times more data, drastically accelerating progress. This new system not only saves time and resources but also paves the way for faster breakthroughs in clean energy, electronics, and sustainability—bringing us closer to a future where lab discoveries happen in days, not y
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
In clinical trials we all want faster results and adaptability. These goals can be achieved with trial standardisation and automation. Both approaches aim to streamline processes, but they differ in focus, speed, and flexibility. Let’s explore the concept of standardising studies, its relationship with automation, and what each approach can offer.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, the gel steadily releases levodopa and carbidopa for seven days, helping keep tremors and stiffness in check while easing side effects linked to fluctuating doses.
The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.
Aplysinopsin analog 12g displayed moderate antiproliferative activity upon breast and cervical cancer cells, and in Zebrafish-based model showed the lethality rate of embryos and larvae, sublethal effects and significant inhibition of larvae growth in a period higher than cytotoxicity assay. In silico ADME analysis indicated 12g with good orally bioavailable.
Neurological diseases are among the most complex and least understood conditions in medicine. Despite the knowledge that certain genes increase the risk of contracting diseases like Alzheimer’s and Parkinson’s, it is still not fully understood how those diseases develop in the brain. But that is beginning to change. At the centre of this shift is 10x Genomics – a company building tools that enable researchers to study individual cells and their gene activity, both in isolation and in their origi
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Sunvozertinib CAS 2370013-12-8 DZD9008, 584.1 g/mol, C 29 H 35 ClFN 7 O 3 , A-1801, L1Q2K5JYO8 N -[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3 R )-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide FDA Zegfrovy, 7/2/2025 To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based c
A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats with cognitive decline, beyond the infamous amyloid and tau plaques long blamed for Alzheimer’s. These shape-shifting proteins don’t clump into visible plaques, making them harder to detect but potentially just as harmful. Scientists believe these “stealth” molecules could evade the brain’s cleanup systems and quietly impair memory and brain function.
Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.
By Jason Campagna, CMO of Q32, as part of the From The Trenches feature of LifeSciVC In a recent essay, I argued that biotech is entering its strategic infrastructure moment, a shift from molecule-centric innovation to a layered capability stack beneath the therapeutic. The core claim was structural: the future of biotech depends as much on what supports the drug as what is in it.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in small molecule drug discovery. Medicinal chemists often describe ADMET optimisation as a frustrating ‘whack-a-mole’ problem: improve one property and another tends to deteriorate.
"Designer Drugs" in the 21st Century "The term “designer drugs” was originally introduced to describe novel substances that are derived from clandestine alterations of well-known drugs of abuse, preserving or enhancing pharmacologic effects while remaining outside of legal control (Jerrard 1990 ). The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval.
Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through neural highways and how certain genes either accelerate its toxic journey or shield brain regions from damage. Their extended Network Diffusion Model pinpoints four gene categories that govern vulnerability or resilience, reshaping our view of Alzheimer’s progression and spotlighting fresh therapeutic targets.
The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.
Risevistinel NYX-783 CAS 2591344-26-0 , UNII-52TU5MZG22 NYX 2925, 2012536-16-0, X062KF5ZV3 C 14 H 23 N 3 O 4 , 297.35 UNII-52TU5MZG22, X062KF5ZV3 (αS,4R)-α-[(1R)-1-Hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-2,5-diazaspiro[3.4]octane-2-acetamide 2,5-Diazaspiro[3.4]octane-2-acetamide, α-[(1 R )-1-hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-, (α S ,4 S )- (2 S ,3 R )-3-hydroxy-2-[(4 S )-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide NYX-783, NYX 2925 CS-0113907 HY-135741 NY
The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues. In a recent conversation with Layla Hosseini-Gerami, Chief Data Science Officer and Co-founder of Ignota Labs , we explored this critical issue, considering how artificial intelligence (AI) and advanced data science approaches may provide solutions.
Drug-drug interactions (DDI) are a significant concern in clinical trials, where the safe and effective administration of drugs to patients is crucial. These interactions can alter the pharmacological activity of one or more drugs, potentially leading to diminished therapeutic effects or unexpected toxic reactions. The complexity of pharmacokinetics and pharmacodynamics, coupled with the variability in patient populations, makes predicting and managing DDI a particularly challenging aspect of dr
Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.
Rezatapopt, PC 14586 CAS 2636846-41-6 Molecular Weight 545.57 Synonyms PC14586 Formula C 28 H 31 F 4 N 5 O 2 CAS No. 2636846-41-6 4-[3-[4-[[(3 S ,4 R )-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy- N -methylbenzamide 4-[3-[4-[[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzamide Benzamide, 4-[[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroe
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
275 
Let's personalize your content